Use of cannabinoids in the treatment of epilepsy

Patent metadata

Field	Value
Publication number	US-9949936-B2
Application number	US-201615284766-A
Country	US
Kind code	B2
Filing date	Oct 4, 2016
Priority date	Jun 17, 2014
Publication date	Apr 24, 2018
Grant date	Apr 24, 2018

Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

First claim

The invention claimed is:

1. A method of treating treatment-resistant epilepsy comprising administering cannabidiol (CBD) to a subject in need thereof, wherein the epilepsy is status epilepticus due to febrile infection related epilepsy syndrome (FIRES).

2. The method of claim 1 , wherein the CBD is administered in combination with two or more concomitant anti-epileptic drugs (AED).

3. The method of claim 2 , wherein the seizure type to be treated is a complex partial seizure (focal seizure with impairment).

4. The method of claim 2 , wherein the CBD is administered in an amount that reduces total convulsive seizure frequency by greater than 70% with respect to the seizure frequency achieved on the concomitant anti-epileptic drugs (AED).

5. The method of claim 2 , wherein the CBD is administered in an amount that reduces total convulsive seizure frequency by greater than 90% with respect to the seizure frequency achieved on the concomitant anti-epileptic drugs (AED).

6. The method of claim 2 , wherein the CBD is administered in an amount that reduces total convulsive seizure frequency by 100% with respect to the seizure frequency achieved on the concomitant anti-epileptic drugs (AED).

7. The method of claim 1 , wherein the CBD is a highly purified extract of cannabis which comprises at least 98% (w/w) CBD.

8. The method of claim 2 , wherein the two or more concomitant anti-epileptic drugs (AED) are administered in combination with the CBD at a dose that is reduced from a recommended therapeutic dose without CBD.

9. The method of claim 8 , wherein the dose of AED which is reduced is of clobazam.

10. The method of claim 1 , wherein the dose of CBD is from 5 mg/kg/day to 25 mg/kg/day.

11. The method of claim 1 , wherein the dose of the CBD is at least 5 mg/kg/day.

12. The method of claim 1 , wherein the dose of the CBD is at least 10 mg/kg/day.

13. The method of claim 1 , wherein the dose of the CBD is at least 15 mg/kg/day.

14. The method of claim 1 , wherein the dose of the CBD is at least 20 mg/kg/day.

Assignees

• Gw Pharma Ltd

Inventors

• Guy Geoffrey
• Wright Stephen
• Mead Alice
• Joshi Charuta
• Wilfong Angus

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/10

  for petit-mal · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K31/195

  having an amino group · CPC title